Summary: This thesis initially conducted an analysis of the prescription group BO4A (Lipid-lowering agents / Antiateromatosos since (
1990-2001) in the National Health System (NHS) and Extremadura. Was found that the more recently marketed (Atorvastatin and [Cerivastatin until his retirement are the increase and cutoas prescription regisstraron. both in the province of Badajoz in the SNS as the withdrawal of Cervibastatina produced an increase in the prescription of atorvastatin. * To be considered regarding US cases of fatal Rhabdomyolysis that happened in the SNS, contrastandose with the database FEDRA, contabilizandose 12 cases, 8 with c erivastatina and 4 with sinvastatina. * prescriptions were analyzed jointly undertaken by doctors in the province of Badajos patients: 1-Cerivastatin and Gemfibrocilo. 2, - Rest of statins and gemifibrocilo. 3-Estaminas associated with antifungilos and macrocidos. * It detects that despite warnings issued by the Spanish agency realizándose prescriptions of the drug remain at risk of interaction. Across the prescription and by the disc billing once localized medical prescribers and patients at risk through telephone notification is requested analytical determination (KPC) obtaining results and realizzandose changes in prescriptions of risk.
